

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 9, 2019

DELMAR PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

Nevada

(State or Other Jurisdiction
of Incorporation)

001-37823

(Commission File Number)

99-0360497

(IRS Employer
Identification No.)

12707 High Bluff Dr., Suite 200
San Diego, CA 92130

(Address of Principal Executive Offices) (Zip Code)

Suite 720-999 West Broadway
Vancouver, British Columbia
Canada V5Z 1K5

(Former name or former address, if changed since last report)

Registrant's telephone number, including area code: (858) 350-4364

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13-e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	DMPI	The Nasdaq Capital Market

Item 8.01. Other Events.

As previously disclosed, on May 22, 2019, DelMar Pharmaceuticals, Inc. (the “Company”) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company was not in compliance with the \$2,500,000 minimum stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) for continued listing on The Nasdaq Capital Market (the “Stockholders’ Equity Requirement”), or with any alternative standard under the Nasdaq Listing Rules.

On September 9, 2019, the Company issued a press release announcing that the Company received notification from the Nasdaq staff (the “Staff”) that the Company regained compliance with the Stockholders’ Equity Requirement based on the Company’s disclosures contained in its Form 8-K filed with the Securities and Exchange Commission on August 16, 2019. The Staff notified the Company that it has regained compliance with the Stockholders’ Equity Requirement for continued listing on The Nasdaq Capital Market and that the matter is now closed.

A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press Release of DelMar Pharmaceuticals, Inc., dated September 9, 2019

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DELMAR PHARMACEUTICALS, INC.

Date: September 9, 2019

By: /s/ Scott Prail
Scott Prail
Chief Financial Officer



DelMar Pharmaceuticals Reports Full Compliance with Nasdaq Listing Criteria

SAN DIEGO, California, September 9, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, today announced that on September 6, 2019, the Company was formally notified by The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained full compliance with all criteria for continued listing on The Nasdaq Capital Market, including the applicable stockholders' equity requirement. Nasdaq's determination follows the previously disclosed \$6.7 million in net proceeds from the underwritten offering completed August 16, 2019.

About DelMar Pharmaceuticals, Inc.

Located in San Diego, California, DelMar is focused on the development and commercialization of new therapies for cancer patients who have limited or no treatment options. By focusing on understanding tumor biology and mechanisms of treatment resistance, the Company identifies biomarkers to personalize new therapies in indications where patients are failing, or are unable to tolerate, standard-of-care treatments.

The Company's current pipeline is based around VAL-083, a "first-in-class", small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors (e.g. NSCLC, bladder cancer, head & neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on DelMar's internal research programs and these prior NCI-sponsored clinical studies, the Company is conducting clinical trials to support the development and commercialization of VAL-083 to solve significant unmet medical needs.

VAL-083 is being studied in two collaborator-supported, biomarker-driven Phase 2 clinical trials for MGMT-unmethylated GBM. Overcoming MGMT-mediated resistance represents a significant unmet medical need in the treatment of GBM. In addition, DelMar has announced the allowance of a separate IND for VAL-083 as a potential treatment for platinum-resistant ovarian cancer.

Further information on DelMar's clinical trials can be found on [clinicaltrials.gov](https://www.clinicaltrials.gov): <https://www.clinicaltrials.gov/ct2/results?cond=&term=val-083&entry1=&state1=&recrs>

For additional information, please visit <http://delmarpharma.com/>; or contact DelMar Pharmaceuticals Investor Relations: ir@delmarpharma.com / (604) 629-5989.



Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the continued listing of the Company's common stock on the Nasdaq Capital Market. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's Annual Report on Form 10-K for the year ended June 30, 2018, the Company's Quarterly Reports on Form 10-Q, and the Company's Current Reports on Form 8-K.

CONTACTS:

Investors:

John Marco
Managing Director
CORE IR
516-222-2560
johnm@coreir.com

Media:

Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com
